KRT14

(redirected from cytokeratin 14)

KRT14

A gene on chromosome 17q12-q21 that encodes a type-I intermediate filament keratin, which typically forms a heterotetramer with KRT5 (type-II) keratins that together form the cytoskeleton of epithelial cells.

Molecular pathology
KRT14 mutations are associated with epidermolysis bullosa simplex.
References in periodicals archive ?
They identified one protein, cytokeratin 14, or K14, that was present in almost all leader cells but was very rare in the noninvasive parts of the tumour.
9) Cytokeratin 14 (CK14) and cytokeratin 17 (CK17) have both been reported as positive immunostains for BCC, (10) although CK14 has not been studied in BCCm.
Cytokeratin 14 stains normal basal keratinocytes of the epidermis (10,34) as well as follicular outer root sheath epithelium.
Primary cutaneous basal cell carcinoma with squamous metaplasia (A, hematoxylin-eosin) stains strongly and diffusely positive (defined as a score of 3 or more than 80% of tumor cells staining) for BerEp4 (B), cytokeratin 14 (C), and cytokeratin 17 (D) immunohistochemical stains (original magnifications X100 [A]).
In myoepithelioma, tumor cells stain positive for S-100 protein, alpha-SMA, muscle-specific actin, vimentin, pankeratin, cytokeratin 7, cytokeratin 14, GFAP, EMA, and calponin.
Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray.
the utility of anti-mitochondrial, caveolin-1, CD63 and cytokeratin 14 antibodies in the differential diagnosis.
By immunohistochemical evaluation, adenoid cystic/ basal cell carcinomas of the prostate are usually positive for high-molecular-weight keratin (clone 34[beta]E12) and cytokeratin 14, at least focally in all cases reported (Figures 3 and 4).
By immunohistochemical evaluation, benign basal cell hyperplasia and adenoid cystic/ basal cell carcinoma share similar patterns of reactivity, expressing high-molecular-weight cytokeratin and cytokeratin 14 and variable positivity for PSA and prostate-specific acid phosphatase.
The antibodies used included monoclonal antibodies against cytokeratin (AE1/AE3) and cytokeratin 14 (BioGenex, San Ramon, Calif), epithelial membrane antigen, vimentin, desmin, actin (HHF35), smooth muscle actin, glial fibrillary acidic protein, and CD34 (Dakopatts a/s, Glostrup, Denmark).
CD34 and cytokeratin 14 were also negative in case 2.